Category
Cancer
Sub Category
Hematology
Study Name
CC-5013-NHL-008/Magnify: A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. The "MAGNIFY" Trial
Principal Investigator
Gordan Srkalovic MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT01996865?term=CC-5013-NHL-008&rank=1
Contact for Questions
Nurse - Vicki 517-364-2811

Site view: at a glance